P21 Guide & Tableau de Dose

What is P21?

P21 — also written as P021 or Peptide 021 — is a small synthetic peptide derived from ciliary neurotrophic factor (CNTF), a naturally occurring protein that helps nerve cells survive and grow. Researchers designed P21 to mimic the helpful parts of CNTF without carrying its drawbacks. It sits in a growing class of compounds called neurotrophic factor small-molecule mimetics — basically, tiny molecules that copy what big brain-support proteins do.^[5] This page is a research-use-only reference. P21 is not approved for human use, and nothing here is medical advice.

How P21 Works

Think of your brain as a garden. Neurotrophic factors are like fertilizer — they help new nerve cells sprout and old ones stay healthy. In Alzheimer's disease and related conditions, that fertilizer supply drops off, and the garden starts to wilt.^[6]

P21 works through two main pathways researchers have identified:

• Blocking a brake signal. It inhibits a signaling molecule called leukemia inhibitory factor (LIF). LIF normally puts the brakes on new neuron growth. By quieting LIF, P21 may allow more neurogenesis — the birth of new brain cells — especially in a memory-critical region called the dentate gyrus.^[5]
• Boosting BDNF. P21 appears to raise levels of brain-derived neurotrophic factor (BDNF), another key growth protein. Higher BDNF activity dials down an enzyme called GSK-3β, which is a major driver of the abnormal tau protein tangles seen in Alzheimer's disease.^[5]

Crucially, P21 is small enough to cross the blood-brain barrier (BBB) — the tight security wall that keeps most large molecules out of the brain — and early research suggests it can be taken orally with favorable pharmacokinetics.^[5]

What the Research Shows

Most P21 evidence comes from preclinical (cell and animal) studies. Here is what researchers have reported so far:

• Neurogenesis and memory. Preclinical studies found that P21 enhanced dentate gyrus neurogenesis and improved memory-related processes in animal models. Researchers linked these effects to its dual action of suppressing LIF signaling and increasing BDNF expression.^[5]
• Tau pathology. Abnormal hyperphosphorylation of tau protein is a hallmark of Alzheimer's. Studies showed P21 robustly reduced this abnormal tau phosphorylation, likely through BDNF-driven reductions in GSK-3β activity — the enzyme that tags tau in harmful ways.^[5]
• Synaptic repair focus. Researchers note that synaptic loss (the shrinking of connections between neurons) correlates with cognitive decline better than plaques or tangles alone. P21's neurotrophic and neurogenic properties make it a candidate for addressing this synaptic deficit directly.^[5]
• Overcoming the CNTF problem. Full-length CNTF protein cannot easily enter the brain, has a short half-life, and caused significant side effects in early human trials. P21 was engineered specifically to sidestep these issues while preserving the beneficial signaling.^[6]
• Neurotrophic imbalance in AD. Studies highlight that Alzheimer's brains show decreased BDNF and neurotrophin-4 in the hippocampus and cortex alongside elevated FGF-2. P21 is being studied as a way to help restore that imbalance.^[6]

It is important to note that all published P21 studies to date are preclinical. Human clinical trial data is not yet available in the peer-reviewed literature covered here.

What P21 Is Being Studied For

• Alzheimer's disease and related neurodegenerative disorders^[5][6]
• Promotion of adult hippocampal neurogenesis^[5]
• Reduction of abnormal tau hyperphosphorylation^[5]
• Synaptic repair and cognitive function preservation^[6]
• As a research tool for understanding CNTF-pathway neurotrophic signaling^[5]

How P21 Is Dosed in Research

Dosing parameters for P21 vary across preclinical studies and depend heavily on the model, route of administration, and research question being asked. Because no standardized human protocol exists, researchers rely on published animal study data as a starting reference point. For a full breakdown of doses reported in the literature, see the dosage chart on this page. To convert between units or scale doses by body weight, use the calculator tool. Always treat these figures as research reference data only.

Mixing and Storing P21

P21 is typically supplied as a lyophilized (freeze-dried) powder and must be reconstituted before use in research settings. Here are general best practices used in laboratory research:

• Reconstitution solvent: Sterile water or a low-concentration acetic acid solution (such as 0.1% acetic acid in sterile water) is commonly used to dissolve peptide powders like P21. Check the supplier's certificate of analysis for specific guidance.
• Mixing: Add solvent slowly to the side of the vial, then gently swirl — do not shake vigorously, as this can degrade the peptide structure.
• Storage before reconstitution: Keep lyophilized peptide at −20 °C or colder, protected from light and moisture.
• Storage after reconstitution: Use reconstituted solution promptly when possible. Aliquot into single-use portions and store at −80 °C to minimize freeze-thaw degradation. Avoid repeated freeze-thaw cycles.
• Contamination control: Use sterile technique throughout. Peptide solutions are not inherently sterile after reconstitution unless filter-sterilized with a 0.22 µm filter.

These are general laboratory guidelines. Specific protocols should follow institutional standards and the requirements of your research design.

Sources

1. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. — DNA repair, 2016. PMID 27156098.
2. An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. — Nature aging, 2021. PMID 35024619.
3. p21 in Cancer Research. — Cancers, 2019. PMID 31416295.
4. Drug Discovery by Targeting Mutant KRAS. — Current topics in medicinal chemistry, 2019. PMID 31762422.
5. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. — Molecular neurodegeneration, 2016. PMID 27400746.
6. Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound. — Biomolecules, 2022. PMID 36291618.